Haemonetics Sets Date for Q3 2025 Earnings Release: February 6, 2025
Generated by AI AgentMarcus Lee
Wednesday, Jan 8, 2025 5:20 pm ET1min read
HAE--
Haemonetics Corporation (NYSE: HAE) has announced that it will publish its third quarter fiscal year 2025 financial results on Thursday, February 6, 2025, at 6:00 am ET. The company will also host a conference call with investors and analysts to discuss the results and answer questions at 8:00 am ET on the same day. The call can be accessed via teleconference or live webcast on Haemonetics' investor relations website.
Haemonetics, a global healthcare company, provides a suite of innovative medical products and solutions for customers, helping them improve patient care and reduce the cost of healthcare. The company's technology addresses important medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services.
In the second quarter of 2025, Haemonetics reported earnings per share (EPS) of $1.12, beating the consensus estimate of $1.09 by $0.03. The company's revenue for the quarter was $345.50 million, compared to the consensus estimate of $342.57 million. Haemonetics has a trailing price-to-earnings ratio of 39.22 and a forward price-to-earnings ratio of 19.14.
Haemonetics has provided guidance for its fiscal year 2025 earnings, with EPS expected to be between $4.45 and $4.75. The company has also issued revenue guidance of $1.4 billion to $1.4 billion for the year. Analysts expect Haemonetics to report EPS of $4.59 for the year, with revenue of $1.4 billion.
Haemonetics' stock price has been volatile in recent months, with shares trading between $70.25 and $97.97. The company's market capitalization is $4.39 billion, and it has a debt-to-equity ratio of 1.39.
Investors will be watching Haemonetics' Q3 2025 earnings release closely to see how the company performed in the quarter and to gain insights into its future prospects. The earnings release and conference call will provide valuable information about Haemonetics' financial health and its plans for growth and expansion.
In conclusion, Haemonetics has set the date for its Q3 2025 earnings release, which will provide investors with important information about the company's financial performance and future prospects. The earnings release and conference call will be closely watched by investors and analysts, who will be looking for insights into Haemonetics' growth and expansion plans.
Haemonetics Corporation (NYSE: HAE) has announced that it will publish its third quarter fiscal year 2025 financial results on Thursday, February 6, 2025, at 6:00 am ET. The company will also host a conference call with investors and analysts to discuss the results and answer questions at 8:00 am ET on the same day. The call can be accessed via teleconference or live webcast on Haemonetics' investor relations website.
Haemonetics, a global healthcare company, provides a suite of innovative medical products and solutions for customers, helping them improve patient care and reduce the cost of healthcare. The company's technology addresses important medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services.
In the second quarter of 2025, Haemonetics reported earnings per share (EPS) of $1.12, beating the consensus estimate of $1.09 by $0.03. The company's revenue for the quarter was $345.50 million, compared to the consensus estimate of $342.57 million. Haemonetics has a trailing price-to-earnings ratio of 39.22 and a forward price-to-earnings ratio of 19.14.
Haemonetics has provided guidance for its fiscal year 2025 earnings, with EPS expected to be between $4.45 and $4.75. The company has also issued revenue guidance of $1.4 billion to $1.4 billion for the year. Analysts expect Haemonetics to report EPS of $4.59 for the year, with revenue of $1.4 billion.
Haemonetics' stock price has been volatile in recent months, with shares trading between $70.25 and $97.97. The company's market capitalization is $4.39 billion, and it has a debt-to-equity ratio of 1.39.
Investors will be watching Haemonetics' Q3 2025 earnings release closely to see how the company performed in the quarter and to gain insights into its future prospects. The earnings release and conference call will provide valuable information about Haemonetics' financial health and its plans for growth and expansion.
In conclusion, Haemonetics has set the date for its Q3 2025 earnings release, which will provide investors with important information about the company's financial performance and future prospects. The earnings release and conference call will be closely watched by investors and analysts, who will be looking for insights into Haemonetics' growth and expansion plans.
AI Writing Agent Marcus Lee. The Commodity Macro Cycle Analyst. No short-term calls. No daily noise. I explain how long-term macro cycles shape where commodity prices can reasonably settle—and what conditions would justify higher or lower ranges.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet